Price Target Changed • 9h
Price target decreased by 7.9% to €3.90 Down from €4.23, the current price target is an average from 6 analysts. New target price is 42% above last closing price of €2.75. Stock is down 64% over the past year. The company is forecast to post earnings per share of €0.42 for next year compared to €0.21 last year. Price Target Changed • Apr 15
Price target decreased by 8.8% to €4.48 Down from €4.92, the current price target is an average from 6 analysts. New target price is 43% above last closing price of €3.15. Stock is down 60% over the past year. The company is forecast to post earnings per share of €0.43 for next year compared to €0.21 last year. Ankündigung • Apr 04
Ontex Group NV, Annual General Meeting, May 05, 2026 Ontex Group NV, Annual General Meeting, May 05, 2026, at 14:00 Romance Standard Time. Location: at the company`s headquarters, located at korte keppestraat 21, 9320 aalst in, Belgium Valuation Update With 7 Day Price Move • Apr 01
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €3.38, the stock trades at a forward P/E ratio of 7x. Average forward P/E is 16x in the Personal Products industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €6.41 per share. Major Estimate Revision • Mar 29
Consensus EPS estimates fall by 21% The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate fell from €0.574 to €0.454 per share. Revenue forecast steady at €1.77b. Net income forecast to grow 104% next year vs 12% growth forecast for Personal Products industry in Belgium. Consensus price target down from €5.38 to €4.92. Share price fell 12% to €3.71 over the past week. Price Target Changed • Mar 27
Price target decreased by 11% to €4.92 Down from €5.53, the current price target is an average from 6 analysts. New target price is 33% above last closing price of €3.71. Stock is down 57% over the past year. The company is forecast to post earnings per share of €0.45 for next year compared to €0.21 last year. Reported Earnings • Mar 20
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: €0.21 (down from €0.26 in FY 2024). Revenue: €1.76b (down 5.3% from FY 2024). Net income: €16.6m (down 21% from FY 2024). Profit margin: 0.9% (down from 1.1% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Major Estimate Revision • Feb 24
Consensus EPS estimates fall by 18% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from €1.79b to €1.78b. EPS estimate also fell from €0.70 per share to €0.574 per share. Net income forecast to grow 186% next year vs 14% growth forecast for Personal Products industry in Belgium. Consensus price target down from €5.53 to €5.38. Share price rose 2.9% to €4.86 over the past week. New Risk • Feb 15
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 41% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Share price has been highly volatile over the past 3 months (7.9% average weekly change). Minor Risk Large one-off items impacting financial results. Reported Earnings • Feb 13
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: €0.21 (down from €0.26 in FY 2024). Revenue: €1.76b (down 5.3% from FY 2024). Net income: €16.6m (down 21% from FY 2024). Profit margin: 0.9% (down from 1.1% in FY 2024). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Ankündigung • Feb 06
Ontex Group NV Launches Sensitive Range to Support Better Skin Health in Incontinence Care Ontex Group NV introduced a new adult incontinence range developed to offer superior protection while being gentle on the skin. The first products -Sensitive Pants, Sensitive Slip and Sensitive Form - will become gradually available for healthcare institutions across Europe. Recent European research conducted by Ontex among more than 2,500 people living with incontinence shows that dermatitis and skin irritation remain widespread and have a meaningful impact on daily life. Almost 1 in 2 people living with incontinence have experienced dermatitis or skin irritation in the intimate area; with many describing significant discomfort and effects on confidence and wellbeing. Despite this high prevalence, These findings underline the urgent need for affordable, qualitative incontinence products that actively support skin health. The new Sensitive range has been developed precisely to answer this need--combining trusted protection with dermatological care to help prevent irritation and keep skin as healthy as possible. To address the educational need, the Sensitive range is complemented with expert training advise on how to recognize, prevent and treat dermatitis related to incontinence. This is offered both through Ontex's network of nurse advisors and through the online training platform Ontex Academy. Sensitive range: powerful protection that respects the skin. The new Sensitive range combines proven incontinence protection with dermatological care. Sensitive Pants offer: Topsheet enriched with botanical ingredients - helps to prevent skin irritation; Innovative Y-core technology - for instant dryness; Faster absorption - up to 2.5x faster than previous iD or Serenity pants; Hypoallergenic design - gentle on fragile skin; Odour control technology - for lasting freshness and confidence. Price Target Changed • Jan 22
Price target decreased by 11% to €5.53 Down from €6.22, the current price target is an average from 6 analysts. New target price is 9.8% above last closing price of €5.04. Stock is down 37% over the past year. The company is forecast to post a net loss per share of €1.58 compared to earnings per share of €0.26 last year. Ankündigung • Jan 22
Ontex Group Nv Launches Multi-Liquid Liner in Europe, Empowering Women in Perimenopause and Menopause Ontex Group NV announced the commercial launch of its multi-liquid liner, now available on shelf at a leading German retailer, with further rollouts planned across Europe in the coming weeks. The launch builds on strong consumer validation following recent tests, with more than 90% of participating women confirming they would recommend Ontex's multi-liquid liner and buy it again. The multi-liquid liner addresses the evolving needs of women in all life stage, offering reliable protection for menstrual flow, light bladder leaks, and daily vaginal discharges--all in one discreet, comfortable solution. Research confirms that liners are widely used by women for menstruation and daily discharges. An important unmet need is protection against light bladder weakness. The liner is specifically designed to address these needs, often related to perimenopause or menopause. Approved as a medical device, the liner features up to 8 hours leak protection and odour control, and is available in three sizes: regular, large, and extra large. Ankündigung • Jan 13
Ontex Group NV Appoints Lorenzo Grabau to the Board Ontex Group NV announced that to strengthen the Board following the resignation of Mr. Jesper Hojer, the Board has co-opted Mr. Lorenzo Grabau as a non-executive director and will submit his ratification at the next shareholders’ meeting. Mr. Grabau brings extensive capital markets and strategic transformation expertise that will be invaluable as Ontex continues to execute its strategic and value creation agenda. Mr. Grabau has considerable experience as director and chair of, and senior advisor to, various listed and non-listed companies. He served as President and CEO of Kinnevik AB. Prior to that, he was a Partner at Goldman Sachs. Major Estimate Revision • Dec 17
Consensus EPS estimates fall by 14% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €1.81b to €1.79b. Losses expected to increase from €1.38 per share to €1.57. Personal Products industry in Belgium expected to see average net income growth of 12% next year. Consensus price target down from €7.58 to €6.53. Share price fell 27% to €4.70 over the past week. New Risk • Dec 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Belgian stocks, typically moving 3.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (51% net debt to equity). Share price has been volatile over the past 3 months (3.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Valuation Update With 7 Day Price Move • Dec 11
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to €5.20, the stock trades at a trailing P/E ratio of 54.8x. Average forward P/E is 16x in the Personal Products industry in Europe. Total loss to shareholders of 17% over the past three years. Ankündigung • Nov 26
Ontex Group NV Launches Dreamshield®? 360 Night Pants Concept with Extra Addition for Long Night Pants - Driving Growth in the Baby Pants Segment Ontex Group NV announced the launch of Dreamshield®? 360 Night Pants, a new night-time concept designed to give babies dry nights and parents greater peace of mind. The new night pants offer extra absorbency for up to 12 hours of protection - especially important for long nights, heavy wetters, extended naps and travel. Ontex's Dreamshield®?360 baby pants are already trusted for nighttime use, and the new night pants build on that foundation by offering parents an even more reassuring solution for prolonged overnight protection. Research confirms that nighttime performance remains a critical priority for families: 75% of parents identify their baby's sleep quality as their top stressor, with nighttime leaks the leading cause of disruption. Parents increasingly look for products that guarantee dryness for longer periods, not just overnight but also during situations that require absorbency designed for high-demand occasions. Recent consumer insights confirm the relevance of stronger night-time protection: parents choose baby pants more often for nighttime across all ages and tend to switch to baby pants sooner at night than during the day. Dreamshield®? 360 Night pants deliver enhanced overnight performance together with the trusted features of the Dreamshield®? 360 Pants range: Extra absorbency for long nights - up to 12 hours of leak-free sleep and extended-use protection; Triple leak protection - including Ontex's unique urine & poo back barrier; Soft, secure 360deg fit - gentle materials and an elastic waistband for comfortable sleeping; Night-time packaging - clear extra absorbency claims and strong night icons for quick and confident shopper navigation; Sustainability at the core - supporting Ontex's targets of CO2 emissions and plastic reduction across its product portfolio. Major Estimate Revision • Nov 07
Consensus EPS estimates upgraded to €0.93 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -€1.54 to -€0.93 per share. Revenue forecast steady at €1.81b. Personal Products industry in Belgium expected to see average net income growth of 12% next year. Consensus price target broadly unchanged at €7.54. Share price was steady at €6.26 over the past week. Ankündigung • Oct 30
Ontex Group NV Maintains Earnings Guidance for Full Year 2025 Ontex Group NV maintained earnings guidance for full year 2025. For the year, the company expects revenue to reduce by low single digit like for like. Major Estimate Revision • Sep 16
Consensus EPS estimates upgraded to €1.54 loss, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from €1.84b to €1.82b. 2025 losses expected to reduce from -€1.98 to -€1.54 per share. Personal Products industry in Belgium expected to see average net income growth of 22% next year. Consensus price target broadly unchanged at €7.68. Share price fell 4.7% to €6.24 over the past week. New Risk • Aug 03
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.4% Last year net profit margin: 1.9% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks High level of debt (51% net debt to equity). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (0.4% net profit margin). Reported Earnings • Aug 03
First half 2025 earnings released: €0.046 loss per share (vs €0.12 profit in 1H 2024) First half 2025 results: €0.046 loss per share (down from €0.12 profit in 1H 2024). Revenue: €880.3m (down 3.9% from 1H 2024). Net loss: €3.70m (down 138% from profit in 1H 2024). Revenue is forecast to grow 3.9% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Major Estimate Revision • Jul 18
Consensus EPS estimates fall by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €1.92b to €1.86b. EPS estimate also fell from €0.892 per share to €0.796 per share. Net income forecast to grow 207% next year vs 17% growth forecast for Personal Products industry in Belgium. Consensus price target down from €10.08 to €7.88. Share price fell 14% to €6.30 over the past week. New Risk • Jul 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Belgian stocks, typically moving 6.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (60% net debt to equity). Share price has been volatile over the past 3 months (6.0% average weekly change). Large one-off items impacting financial results. Ankündigung • Apr 30
Ontex Group NV to Report Q4, 2025 Results on Feb 12, 2026 Ontex Group NV announced that they will report Q4, 2025 results on Feb 12, 2026 Reported Earnings • Feb 21
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: €0.26 (down from €0.33 in FY 2023). Revenue: €1.86b (up 3.7% from FY 2023). Net income: €21.0m (down 22% from FY 2023). Profit margin: 1.1% (down from 1.5% in FY 2023). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 72%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has increased by 83% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Ankündigung • Feb 21
Ontex Group Nv Provides Earnings Guidance for the Year 2025 Ontex Group NV provided earnings guidance for the year 2025. For the year, the company expected revenue to grow by 3% to 5% like for like, supported by double-digit volume growth in North America. Ankündigung • Feb 17
Ontex Group NV Introduces Dreamshields Technology in Baby Diapers Across Europe Ontex Group NV announced the commercial launch of its Dreamshields technology for baby diapers. Offering superior performance, all-round leakage protection, and enhanced comfort, Dreamshields ensures optimal dryness while prioritizing sustainability. The Dreamshields technology is now available on shelf in several European markets in Europe, and being rolled out to more customers soon. Dreamshields technology integrates a range of advanced features that benefit both parents and babies, enhancing comfort, Dreamshields, protection, and ease of use. Consumers have responded positively to the innovative technologies. Panel scores show Dreamshields® performs great, especially when it comes to leakage protection. These innovations address both the needs of babies for comfort and the expectations of parents for reliability and sustainability: Unique channel design with gender-specific zones: enhances fast liquid flow across the entire core for superior absorption, ensuring babies stay dry and comfortable; SeconDRY® system: provides instant dryness by rapidly drawing moisture away from the skin, minimizing the risk of irritation; Double-layer core with dual SAP (Super Absorbent Polymer): features two types of SAP, optimizing fast liquid attraction and solid retention for a lighter, more flexible diaper; 360deg protection: combines front and back barriers with anti-leak cuffs, effectively preventing leaks and blow-outs in all directions; Heat release feature: promotes air circulation, maintaining fresh and healthy skin conditions to prevent comfort and rashes; High waist fit: offers a snug and stretchy fit that adapts to baby's movements, ensuring comfort at all times. Board Change • Nov 21
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Non-Executive Director Ebrahim Attarzadeh was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Nov 01
Consensus EPS estimates fall by 17% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate fell from €0.507 to €0.423 per share. Revenue forecast steady at €1.86b. Net income forecast to grow 75% next year vs 35% growth forecast for Personal Products industry in Belgium. Consensus price target broadly unchanged at €11.20. Share price fell 2.9% to €7.69 over the past week. Ankündigung • Oct 24
Ontex Group NV to Report Q3, 2025 Results on Oct 30, 2025 Ontex Group NV announced that they will report Q3, 2025 results on Oct 30, 2025 Ankündigung • Aug 29
Ontex Group NV Brings Its Dreamshield® 360o Technology in Baby Pants to Market Across Europe Ontex Group NV announced the commercial launch of its newest baby pants, featuring its Dreamshield® 360o innovation. The Dreamshield® 360deg technology - designed with a unique urine & poo back barrier and a 360 fit for all-around protection and comfort - is available in-stores in Germany. The launch will soon expand to other markets as production ramps up across Ontex plants. Consumer preference confirmed by consumer panel testing: Dreamshield® 360º pants have demonstrated superior performance in multiple consumer panels versus competitor products. Consumers have expressed their preference for Dreamshield® 360º, particularly related to absorption capacity, absence of leaks, dryness and fit. In a recent French study, 65% of consumers considered absorption capacity in baby products to be extremely important, while 55% emphasized the need to keep skin dry, and 62% rated comfort as a crucial factor. Dreamshield® 360º excelled in panels against competitors in all these areas, making it a trusted choice among both parents and retailers. The new range of baby pants features triple leakage barriers and continues to use Ontex’s patented SeconDRY® technology, ensuring all-around anti-leak fit and ultimate dryness. Strong market demand for baby pants: Ontex saw strong growth in its baby pants sales last year and this trend continues in 2024. The rollout of the baby pant technology has started in Europe with room for expansion to other regions. The production follows the demand of retailers across Europe, who saw the results of Dreamshield® 360º in the German consumer panel1 and see how their consumers shift to baby pants over traditional diapers, both in Europe and North America. Lab and panel test by independent Hytec lab in Germany, fourth quarter 2023. Ankündigung • Jul 23
Ontex Group NV Announces the Launch of Enhanced Youth Pants This Fall Ontex Group NV announced the launch of enhanced youth pants this fall. The pants are designed to reduce the psychological impact of incontinence during adolescence, offering protection and discretion. The new Ontex youth pants are tailored for children aged 3 to 15 who struggle with bladder control at night, despite staying dry during the day, or have some disability leading to loss of bladder control. The pants are produced by Ontex plants using its growing HappyFit product platform and will be available through retailers and Ontex's online sales channels in Europe, with room for expansion to other regions. The pants are constructed combining absorbent materials for heavy bedwetting protection, a chassis with soft and quiet materials for discretion that also offers an improved fit. The production will also have a significantly lower impact on the environment vs previous concepts. During the production, waste is also minimized. Ankündigung • Jun 15
Ontex Group NV Announces Intention to Restructure Its Production and Distribution Activities in Belgium Ontex Group NV announced the intention to restructure its Belgian production and distribution activities, as part of its strategic transformation to strengthen its competitive position in the European market. This intended restructuring would entail the closure of the Eeklo site, as well as the transformation of the Buggenhout site into a Center of Excellence for research, development and production of medium & heavy incontinence care products, enabled by investments in the range of €40 million. The intended restructuring would lead to the reduction of 489 employees in Eeklo and Buggenhout, bringing the total workforce in Belgium to 569 positions, spread over the Buggenhout and Aalst sites. In response to the increasingly competitive personal care market, Ontex is implementing its global transformation plan to strengthen its competitiveness, with a strong focus on customer-centricity, sustainable innovation and organizational and operational cost-efficiency. Since the launch of the transformation plan, numerous initiatives have been implemented, enabling the Group to improve its financial results. These early results provide confidence to pursue the structural transformation to regain and strengthen competitiveness. The intended optimization of Ontex’s Belgian production and distribution activities is an essential strategic initiative aimed at strengthening Ontex’s operational cost-efficiency across Europe. Consequently, Ontex announced its intention to transform its Belgian operations footprint by exiting the Eeklo site and transforming the Buggenhout site into a center of excellence for medium and heavy incontinence products. The intended closure of the Eeklo site would have an impact on all current 349 production-related employees, and the intended reorganization of the Buggenhout site would impact 140 out of 528 employees. Today, the works councils in Eeklo and Buggenhout were informed in line with the legal information and consultation procedure. If – following consultation with the works councils - the intention would be confirmed, the legal procedure would be followed and Ontex would do its utmost best to offer support to all employees involved. In Belgium, Ontex would continue to employ 569 employees, based in Buggenhout and Aalst. Ankündigung • May 25
Ontex Group NV Launches Stop&Lock Anti-Leak Technology for Enhanced Baby Comfort and Protection Ontex Group NV announced the introduction of its innovative Stop&Lock Anti-Leak technology in baby care. The Ontex innovation entails the introduction of front and back barriers in newborn and mini sizes of baby diapers, which Ontex produces for retailer partners. Ontex Stop&Lock Anti-Leak technology has been successfully introduced in selected baby diapers in North America and will be launched at a major European retailer in June. Along with leg barriers, Stop&Lock Anti-Leak technology provides 360-degree leakage protection to contain poo explosions, a common issue with newborns fed on breastmilk or formula. This enhances baby comfort and eases parental concerns about major leaks, an important consumer motivator according to research. A 2024 panel test in Europe indicates that 20% of parents surveyed expressed concern about these significant diaper leaks, with many reporting that leaks disrupt outings, as well as their baby’s sleep and play. In response, Ontex front & back barriers ensure 4-side leak protection from both urine and liquid stool. This feature of Ontex Stop&Lock Anti-Leak technology is designed to significantly reduce the need for frequent and complete outfit changes due to leakage incidents. Ankündigung • May 03
Ontex Group NV Provides Earnings Guidance for the Year 2024 Ontex Group NV provided earnings guidance for the year 2024. For the year, the company confirms its previously iterated guidance, expecting: Revenue to grow by low single-digit like for like, supported by strong double-digit growth in North America, while managing prices in function of input costs and market dynamics. Price Target Changed • Apr 15
Price target increased by 9.3% to €10.99 Up from €10.06, the current price target is an average from 6 analysts. New target price is 25% above last closing price of €8.77. Stock is up 12% over the past year. The company is forecast to post earnings per share of €0.99 for next year compared to €0.33 last year. Ankündigung • Apr 03
Ontex Group NV to Report Q4, 2024 Results on Feb 12, 2025 Ontex Group NV announced that they will report Q4, 2024 results on Feb 12, 2025 Ankündigung • Apr 02
Hygianis SPA completed the acquisition of Algerian business of Ontex Group. Hygianis SPA entered into a binding agreement to acquire Algerian business of Ontex Group on August 9, 2023. The transaction includes Ontex’s business in Algeria and related exports to certain neighboring countries. Ontex’s business in Algeria generated about €50 million sales in 2022, and is part of Ontex’s emerging markets activities, which have been classified as discontinued operations following the strategic decision in 2021 to divest these. Ontex aims to close the transaction, which is subject to customary conditions, by the end of September 2023.
Hygianis SPA completed the acquisition of Algerian business of Ontex Group on April 2, 2024. The cash proceeds prior to taxes and transaction costs are approximately €25 million and remain subject to customary post-closing adjustments. Major Estimate Revision • Mar 27
Consensus EPS estimates increase by 23% The consensus outlook for fiscal year 2024 has been updated. 2024 EPS estimate increased from €0.81 to €0.997. Revenue forecast steady at €1.85b. Net income forecast to grow 182% next year vs 25% growth forecast for Personal Products industry in Belgium. Consensus price target of €10.16 unchanged from last update. Share price rose 3.2% to €7.56 over the past week. New Risk • Feb 11
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 26% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.0x net interest cover). Minor Risk Large one-off items impacting financial results. Reported Earnings • Feb 09
Full year 2023 earnings: EPS and revenues exceed analyst expectations Full year 2023 results: EPS: €0.33 (up from €1.84 loss in FY 2022). Revenue: €1.79b (up 7.3% from FY 2022). Net income: €26.9m (up €175.6m from FY 2022). Profit margin: 1.5% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue exceeded analyst estimates by 30%. Earnings per share (EPS) also surpassed analyst estimates significantly. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Ankündigung • Feb 08
Ontex Group NV Provides Earnings Guidance for the Year 2024 Ontex Group NV provided earnings guidance for the year 2024. For the period, the company expects Revenue to grow by low single-digit like for like, supported by strong double-digit growth in North America, while managing prices in function of input costs and market dynamics. Ankündigung • Oct 27
Ontex Appoints Geert Peeters as Chief Financial Officer, Effective December 1, 2023 Ontex announces the appointment of Geert Peeters as Chief Financial Officer, effective December 1, 2023. Until recently, Geert was Group CFO at Greenyard (Euronext: GREENYARD). He built up vast experience through finance director roles at companies such as Metallo Group (currently Aurubis) and management consultancies such as PriceWaterhouseCoopers. Ankündigung • Sep 06
Ontex Group NV Announces Change of Chief Financial Officer, Effective Early October 2023 Ontex Group NV announced that Peter Vanneste, Chief Financial Officer at Ontex, has decided to leave Ontex early October 2023, to pursue a career opportunity outside the Group. His successor will be announced in due time. In the interim the responsibilities of CFO will be assumed by Gustavo Calvo Paz, CEO. Ankündigung • Aug 11
Hygianis SPA entered into a binding agreement to acquire Algerian business of Ontex Group. Hygianis SPA entered into a binding agreement to acquire Algerian business of Ontex Group on August 9, 2023. The transaction includes Ontex’s business in Algeria and related exports to certain neighboring countries. Ontex’s business in Algeria generated about €50 million sales in 2022, and is part of Ontex’s emerging markets activities, which have been classified as discontinued operations following the strategic decision in 2021 to divest these. Ontex aims to close the transaction, which is subject to customary conditions, by the end of September 2023. Reported Earnings • Jul 30
First half 2023 earnings released: EPS: €0.025 (vs €1.23 loss in 1H 2022) First half 2023 results: EPS: €0.025 (up from €1.23 loss in 1H 2022). Revenue: €891.8m (up 14% from 1H 2022). Net income: €2.00m (up €101.8m from 1H 2022). Profit margin: 0.2% (up from net loss in 1H 2022). Revenue is forecast to grow 2.3% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 85 percentage points per year, which is a significant difference in performance. Ankündigung • Jul 29
Ontex Group NV, Annual General Meeting, May 08, 2024 Ontex Group NV, Annual General Meeting, May 08, 2024. Reported Earnings • Mar 06
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2022 results: €1.84 loss per share (further deteriorated from €0.77 loss in FY 2021). Revenue: €1.67b (down 18% from FY 2021). Net loss: €148.7m (loss widened 140% from FY 2021). Revenue exceeded analyst estimates by 16%. Earnings per share (EPS) missed analyst estimates by 108%. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Personal Products industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Mar 03
Consensus EPS estimates increase by 15% The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from €0.673 to €0.774. Revenue forecast steady at €2.22b. Net income forecast to grow 72% next year vs 8.4% growth forecast for Personal Products industry in Belgium. Consensus price target of €9.42 unchanged from last update. Share price rose 3.4% to €7.50 over the past week. Buying Opportunity • Mar 03
Now 20% undervalued Over the last 90 days, the stock is up 16%. The fair value is estimated to be €9.35, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.1% over the last 3 years. Meanwhile, the company became loss making. Revenue is forecast to grow by 2.5% in a year. Earnings is forecast to grow by 72% in the next year. Major Estimate Revision • Nov 16
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €2.14b to €2.07b. 2022 losses expected to reduce from -€1.58 to -€1.38 per share. Personal Products industry in Belgium expected to see average net income growth of 9.2% next year. Consensus price target broadly unchanged at €9.82. Share price fell 3.4% to €5.98 over the past week. Board Change • Nov 16
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Paul McNulty was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Major Estimate Revision • Oct 07
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -€0.76 to -€1.18 per share. Revenue forecast unchanged at €2.16b. Personal Products industry in Belgium expected to see average net income growth of 8.8% next year. Consensus price target broadly unchanged at €9.80. Share price was steady at €5.58 over the past week. Reported Earnings • Aug 03
First half 2022 earnings released First half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down €7.20m from profit in 1H 2021). Profit margin: (down from 0.7% in 1H 2021). Over the next year, revenue is forecast to grow 1.8%, compared to a 7.7% growth forecast for the industry in Belgium. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Aug 02
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €2.09b to €2.12b. Forecast EPS reduced from -€0.61 to -€0.75 per share. Personal Products industry in Belgium expected to see average net income growth of 5.4% next year. Consensus price target of €9.86 unchanged from last update. Share price fell 8.0% to €6.14 over the past week. Major Estimate Revision • May 22
Consensus estimates of losses per share improve by 37% The consensus outlook for earnings per share (EPS) in 2022 has improved. 2022 revenue forecast increased from €2.05b to €2.19b. EPS estimate increased from -€0.93 per share to -€0.59 per share. Personal Products industry in Belgium expected to see average net income growth of 4.3% next year. Consensus price target broadly unchanged at €9.69. Share price was steady at €7.46 over the past week. Price Target Changed • May 12
Price target increased to €9.56 Up from €8.84, the current price target is an average from 8 analysts. New target price is 26% above last closing price of €7.61. Stock is down 31% over the past year. The company is forecast to post a net loss per share of €0.11 next year compared to a net loss per share of €0.76 last year. Major Estimate Revision • Apr 27
Consensus EPS estimates have been downgraded. The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €2.11b to €2.04b. Now expected to report a loss of €0.11 per share instead of €0.10 per share profit previously forecast. Personal Products industry in Belgium expected to see average net income growth of 8.1% next year. Consensus price target broadly unchanged at €8.80. Share price rose 3.4% to €6.55 over the past week. Board Change • Apr 27
Less than half of directors are independent There are 8 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Director Manon Janssen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Major Estimate Revision • Apr 21
Consensus EPS estimates fall by 51% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from €2.11b to €2.04b. EPS estimate also fell from €0.10 per share to €0.05 per share. Net income forecast to grow 64% next year vs 16% growth forecast for Personal Products industry in Belgium. Consensus price target down from €8.84 to €8.52. Share price fell 7.3% to €6.33 over the past week. Reported Earnings • Apr 07
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: €0.77 loss per share (down from €0.67 profit in FY 2020). Revenue: €2.03b (down 2.9% from FY 2020). Net loss: €61.9m (down 215% from profit in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 3.9%, compared to a 9.4% growth forecast for the industry in Belgium. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Mar 15
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 forecast for profit of -€0.03 instead of a loss of €0.10 per share previously. Revenue forecast unchanged at €2.11b. Personal Products industry in Belgium expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at €8.84. Share price rose 11% to €7.02 over the past week. Reported Earnings • Feb 24
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: €0.77 loss per share (down from €0.67 profit in FY 2020). Revenue: €2.03b (down 2.9% from FY 2020). Net loss: €61.9m (down 215% from profit in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 2.9%, compared to a 8.5% growth forecast for the industry in Belgium. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 35 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Jan 19
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate fell from €0.19 to €0.13 per share. Revenue forecast steady at €2.03b. Net income forecast to shrink 26% next year vs 9.2% growth forecast for Personal Products industry in Belgium . Consensus price target of €9.56 unchanged from last update. Share price was steady at €7.13 over the past week. Major Estimate Revision • Jan 12
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate fell from €0.19 to €0.15 per share. Revenue forecast steady at €2.03b. Net income forecast to shrink 1.0% next year vs 13% growth forecast for Personal Products industry in Belgium . Consensus price target broadly unchanged at €9.56. Share price fell 3.3% to €7.17 over the past week. Price Target Changed • Dec 22
Price target decreased to €9.56 Down from €10.31, the current price target is an average from 10 analysts. New target price is 43% above last closing price of €6.70. Stock is down 37% over the past year. The company is forecast to post earnings per share of €0.19 for next year compared to €0.67 last year. Major Estimate Revision • Dec 17
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 EPS estimate increased from €0.14 to €0.19. Revenue forecast steady at €2.03b. Net income forecast to grow 34% next year vs 16% growth forecast for Personal Products industry in Belgium. Consensus price target down from €10.47 to €9.85. Share price fell 13% to €6.83 over the past week. Price Target Changed • Nov 03
Price target decreased to €10.22 Down from €11.17, the current price target is an average from 10 analysts. New target price is 29% above last closing price of €7.91. Stock is down 14% over the past year. The company is forecast to post earnings per share of €0.17 for next year compared to €0.67 last year. 
